29 Leading Oligonucleotide CDMO Companies Shaping Innovation and Market Growth to 2031

Discover the top 29 companies driving innovation in the oligonucleotide contract development and manufacturing organization (CDMO) market. This in-depth analysis explores competitive strengths, manufacturing capabilities, and emerging trends shaping oligonucleotide therapeutics, process development, and commercial-scale production through 2031. Access the comprehensive market research report for further insights.

Spotlights on the Industry's Top Oligonucleotide CDMO Companies

The oligonucleotide CDMO industry is expanding as pharmaceutical and biotechnology companies advance antisense oligonucleotide (ASO), small interfering RNA (siRNA), and other nucleic acid-based therapeutic programs. Manufacturers are investing in specialized synthesis platforms, purification technologies, analytical development, process optimization, and good manufacturing practice (GMP) production to meet increasingly complex requirements. Demand is also growing for integrated services that support programs from early development through clinical trials and commercial supply. However, manufacturing complexity, impurity control, scale-up, production costs, and stringent quality expectations remain important considerations. Providers with appropriate technical expertise, scalable infrastructure, and robust quality systems are positioned to support the industry's evolving needs.

1. Bachem Inc.

Bachem specializes in the development and manufacture of peptides and complex organic molecules for pharmaceutical and biotechnology applications. Its expertise in active pharmaceutical ingredient (API) development, process chemistry, analytical services, and GMP manufacturing is relevant to the broader oligonucleotide CDMO ecosystem. As nucleic acid-based therapies grow in importance, specialized chemistry, process control, and reliable production become increasingly critical. Bachem's established experience in complex molecule manufacturing supports its relevance to advanced therapeutic development, although its core business remains strongly associated with peptide APIs.

2. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific supports oligonucleotide development and manufacturing through its pharmaceutical services infrastructure and broad portfolio of laboratory technologies. Its CDMO capabilities can help pharmaceutical and biotechnology companies advance development programs, while its reagents, analytical instruments, and consumables support oligonucleotide characterization and quality control. Integrated development and manufacturing resources are important as ASO and siRNA candidates move from research into clinical and commercial production. The company's global operating scale and broad scientific services portfolio make it a significant participant in the wider oligonucleotide manufacturing landscape.

3. Agilent Technologies, Inc.

Agilent Technologies is a prominent provider of oligonucleotide synthesis systems, custom oligonucleotide manufacturing, process development, and GMP production services. Its capabilities support the development and manufacture of nucleic acid-based therapeutics, with services spanning analytical development, purification, and quality testing. These activities help customers address the technical challenges of producing high-quality oligonucleotides for clinical and commercial use. Agilent's experience in oligonucleotide chemistry and analytical instrumentation strengthens its position among suppliers serving pharmaceutical and biotechnology companies seeking specialized manufacturing and characterization capabilities.

4. WuXi AppTec

WuXi AppTec provides research, development, testing, and manufacturing services to pharmaceutical and biotechnology companies. Its oligonucleotide services support programs requiring process development, analytical testing, synthesis, and manufacturing across development stages. The company's integrated contract research and manufacturing model can help clients coordinate complex workflows as nucleic acid-based candidates progress toward clinical and commercial supply. Its global service network and broad drug development expertise are relevant to sponsors seeking outsourced capabilities, although customers must assess facility, jurisdiction, and regulatory requirements for each program.

5. Maravai LifeSciences

Maravai LifeSciences serves the life sciences sector through specialized products and services supporting nucleic acid-based research and therapeutic development. Its TriLink Biotechnologies business is known for nucleic acid manufacturing, including modified nucleotides, mRNA-related materials, and custom RNA products. These capabilities are relevant to developers working with advanced genetic medicines and other nucleic acid technologies. Maravai's experience in specialized nucleic acid chemistry and research-grade materials supports its role in the supply chain, while the precise manufacturing scope depends on the molecule, scale, and quality requirements.

6. Lonza

Lonza provides contract development and manufacturing services across pharmaceuticals and advanced therapeutic modalities. Its capabilities in process development, analytical services, and GMP manufacturing are relevant to companies advancing complex oligonucleotide-based medicines. As developers seek reliable transitions from early-stage work to clinical and commercial supply, integrated development expertise and quality systems become important selection criteria. Lonza's global manufacturing network and experience supporting pharmaceutical production strengthen its relevance to the CDMO sector. Specific oligonucleotide capabilities and capacity should be evaluated against each sponsor's modality and production requirements.

7. Eurofins Scientific

Eurofins Scientific operates a broad network of analytical testing and laboratory service businesses supporting pharmaceutical, biotechnology, chemical, and other industries. Its scientific services can contribute to oligonucleotide programs through analytical characterization, quality testing, and related laboratory support, depending on the selected business unit and service offering. Reliable analytical methods are essential for evaluating identity, purity, impurities, and consistency in oligonucleotide production. Eurofins' laboratory infrastructure and analytical expertise make it relevant to the wider manufacturing ecosystem, although its role should be distinguished from dedicated large-scale oligonucleotide API production.

8. Danaher Corporation

Danaher Corporation participates in the oligonucleotide ecosystem through its life sciences businesses and associated research technologies. Integrated DNA Technologies (IDT), part of Danaher, supplies custom oligonucleotides and nucleic acid-related products used in molecular biology, genomics, and research applications. These products can support therapeutic research and development, although research-scale synthesis is distinct from GMP manufacturing of therapeutic APIs. Danaher's broader life sciences portfolio provides tools and technologies used across biological research and bioprocessing, making its relevance dependent on the specific subsidiary, product, and manufacturing stage involved.

9. GenScript

GenScript provides life science research services and products, including custom nucleic acid synthesis and molecular biology solutions. Its oligonucleotide-related offerings support applications such as gene synthesis, molecular diagnostics, and research workflows, while its broader contract research capabilities serve biotechnology and pharmaceutical customers. Reliable custom synthesis and sequence-specific production are important to early-stage oligonucleotide research and development. GenScript's established presence in gene and nucleic acid services makes it relevant to the supply chain, though the scale, GMP status, and suitability of any particular service should be confirmed for therapeutic manufacturing programs.

10. Syngene International Limited

Syngene International provides contract research, development, and manufacturing services to pharmaceutical, biotechnology, and other life science companies. Its integrated research capabilities support drug discovery, development chemistry, analytical testing, and selected manufacturing requirements. These services can contribute to oligonucleotide programs where process development, characterization, and outsourced scientific support are needed. As nucleic acid-based therapies become more complex, customers increasingly seek partners capable of coordinating multiple development activities. Syngene's broad contract research model makes it relevant to the wider CDMO landscape, with specific oligonucleotide manufacturing scope requiring confirmation.

11. EuroAPI

EuroAPI develops and manufactures active pharmaceutical ingredients and provides related development and production services to pharmaceutical customers. Its experience in API process chemistry, industrial manufacturing, quality management, and regulated production is relevant to the broader CDMO sector. However, conventional small-molecule API manufacturing differs technically from oligonucleotide synthesis, purification, and impurity control. EuroAPI's role in this market should therefore be assessed against its currently available nucleic acid-specific capabilities rather than inferred from its pharmaceutical manufacturing expertise alone. Sponsors should verify modality coverage and GMP capacity before considering it for oligonucleotide projects.

12. Ajinomoto Co., Inc.

Ajinomoto Co., Inc. has a broad portfolio spanning amino acid chemistry, biotechnology, and pharmaceutical-related services. Its life sciences and biopharmaceutical activities provide expertise in specialized manufacturing processes, quality systems, and complex biochemical production. These capabilities are relevant to the broader advanced therapeutics supply chain, although amino acid and peptide technologies should not be treated as equivalent to oligonucleotide API manufacturing. Its inclusion in the oligonucleotide CDMO landscape makes it important to distinguish established adjacent capabilities from specific nucleic acid synthesis, purification, and GMP services that must be confirmed for each project.

13. ST Pharm

ST Pharm is a major participant in oligonucleotide development and manufacturing, serving pharmaceutical and biotechnology companies developing nucleic acid-based therapeutics. Its capabilities include oligonucleotide process development, synthesis, purification, analytical development, and GMP manufacturing for modalities such as ASOs and siRNA. Integrated manufacturing and expertise in nucleic acid chemistry help address challenges associated with product quality, scalability, and supply continuity. As more oligonucleotide candidates advance through clinical development, ST Pharm's specialized infrastructure and focus on nucleic acid production position it as an important supplier in the global CDMO landscape.

14. Kaneka Corporation

Kaneka Corporation operates across chemicals, materials, healthcare, and life sciences. Through its biotechnology and pharmaceutical-related activities, including businesses associated with specialized nucleic acid and biological production, the company participates in the broader advanced therapeutics supply chain. Its relevance to oligonucleotide CDMO services depends on the specific subsidiary and service, since capabilities in biotechnology or biologics do not automatically establish equivalent expertise in therapeutic oligonucleotide synthesis. Customers evaluating Kaneka should confirm available modalities, manufacturing scale, analytical capabilities, and GMP coverage for their intended oligonucleotide program.

15. Polypeptide Group

PolyPeptide Group specializes in the development and manufacture of peptide-based active pharmaceutical ingredients for pharmaceutical and biotechnology customers. Its strengths include peptide chemistry, process development, purification, analytical testing, and GMP production. These capabilities are relevant to the wider complex-molecule manufacturing sector, particularly as some advanced therapies involve both peptide and nucleic acid components. However, peptide manufacturing and oligonucleotide synthesis require distinct chemistries and production processes. PolyPeptide Group's direct role in oligonucleotide CDMO services should therefore be verified rather than assumed from its established position in peptide manufacturing.

16. Aurigene Pharmaceutical Services Ltd.

Aurigene Pharmaceutical Services provides drug discovery, development, and contract research services to pharmaceutical and biotechnology companies. Its scientific capabilities support early-stage research, medicinal chemistry, biology, and development programs. Such expertise can be relevant to the discovery and evaluation of oligonucleotide-based candidates, particularly where sponsors need integrated research support. However, drug discovery services are distinct from specialized oligonucleotide API manufacturing at GMP scale. Companies considering Aurigene for an oligonucleotide program should confirm the availability of sequence-specific synthesis, purification, analytical development, and regulated manufacturing services for the required modality.

17. BioSpring

BioSpring specializes in oligonucleotide development and manufacturing for pharmaceutical and biotechnology customers. Its services support the production of nucleic acid-based therapeutics, including process development, analytical characterization, purification, and GMP manufacturing. The company serves programs that require careful control of sequence integrity, impurities, and batch consistency as they move through clinical development and toward commercialization. Its dedicated focus on oligonucleotide chemistry and manufacturing makes BioSpring relevant to developers seeking a specialist partner for complex nucleic acid APIs and scalable production processes.

18. Nippon Shokubai Co., Ltd.

Nippon Shokubai is a chemical manufacturer with expertise in materials, catalysts, acrylic products, and specialty chemicals. Its industrial chemistry capabilities may be relevant to the wider supply chain supporting pharmaceutical and advanced biotechnology manufacturing. However, specialty chemical manufacturing alone does not establish direct capability in therapeutic oligonucleotide synthesis or GMP API production. Its role in the oligonucleotide CDMO market should be confirmed against specific nucleic acid-related products, services, or business units. Buyers should verify the availability of oligonucleotide-specific process development, purification, and quality systems before considering the company as a direct CDMO.

19. LGC Biosearch Technologies

LGC Biosearch Technologies provides genomic and life science products, including custom oligonucleotides, probes, and reagents used in molecular biology and genomics. Its offerings support research, assay development, genotyping, and other applications that rely on sequence-specific nucleic acid materials. These products can contribute to early research and analytical workflows relevant to oligonucleotide development. Its role spans specialized oligonucleotide supply and life science technologies; customers developing therapeutic APIs should distinguish research and diagnostic products from GMP-grade manufacturing services and confirm the specifications required for regulated applications.

20. Oligo Factory

Oligo Factory focuses on custom oligonucleotide synthesis for research and biotechnology applications. Sequence-specific oligonucleotides are essential tools in molecular biology, genomics, assay development, and early-stage therapeutic research. Suppliers in this segment support customers through custom synthesis, modification options, and product quality tailored to the intended application. For programs moving toward clinical or commercial drug supply, requirements extend beyond research oligos to validated processes, stringent impurity control, and GMP documentation. Customers should verify Oligo Factory's current production scale, therapeutic modalities, and regulatory manufacturing capabilities for their specific needs.

21. Corden Pharma

Corden Pharma provides contract development and manufacturing services for pharmaceutical companies, with expertise in complex APIs, process development, analytical services, and GMP production. Its established experience in regulated pharmaceutical manufacturing is relevant to the broader CDMO sector. Oligonucleotide production, however, requires specialized synthesis, purification, and analytical capabilities that differ from many conventional API processes. Corden Pharma's suitability for a specific oligonucleotide program should be determined by confirming the current scope of its nucleic acid services, available production capacity, and ability to support the required clinical or commercial stage.

22. Bio-Synthesis, Inc.

Bio-Synthesis, Inc. supplies custom oligonucleotides, peptides, antibodies, and related research products and services. Its oligonucleotide offerings support molecular biology, gene expression studies, assay development, and other applications requiring sequence-specific nucleic acid materials. Custom synthesis and modification services can help researchers obtain materials suited to their experimental designs. For therapeutic development, additional requirements may include GMP manufacturing, validated analytical methods, and comprehensive impurity characterization. Customers should confirm whether the company's current service offering and manufacturing controls meet the scale and regulatory standards needed for clinical or commercial oligonucleotide APIs.

23. Microsynth

Microsynth provides custom DNA and RNA oligonucleotides, sequencing, and molecular biology services for research, diagnostics, and biotechnology applications. Its synthesis capabilities support applications such as PCR, molecular assays, genomics, and research into nucleic acid-based technologies. Reliable sequence-specific production is an important part of the early oligonucleotide development workflow. Microsynth's established position in custom oligonucleotide supply makes it relevant to the broader ecosystem, although research and diagnostic synthesis should be distinguished from therapeutic GMP manufacturing. Sponsors should verify product specifications, production scale, and quality requirements for regulated drug development.

24. SynoLigo Biotechnologies, Inc.

SynoLigo Biotechnologies focuses on oligonucleotide synthesis and related services for research and therapeutic development. Its offerings are relevant to programs that require custom nucleic acid materials, including modified sequences and specialized oligonucleotide constructs. Such capabilities can support early research and the development of nucleic acid-based medicines, where sequence accuracy and impurity control are important. For clinical and commercial programs, sponsors must also assess process validation, analytical characterization, GMP compliance, and manufacturing scale. SynoLigo's fit depends on the specific oligonucleotide modality and the quality standards required by each project.

25. Hongene Biotech Corporation

Hongene Biotech Corporation provides oligonucleotide CDMO services alongside nucleic acid manufacturing materials. Its capabilities span process and analytical development, GMP manufacturing, and quality control for modalities including ASOs, siRNA, aptamers, and oligonucleotide conjugates. The company also supplies phosphoramidites, modified nucleotides, linkers, and other raw materials used in oligonucleotide production. Combining material supply with development and manufacturing can help customers address supply chain and process continuity needs. Hongene's integrated platform is relevant to developers seeking support from early-stage work through clinical and commercial production.

26. Sylentis, S.A.

Sylentis is a biotechnology company focused on RNA interference-based therapeutics, including the development of siRNA candidates for disease treatment. Its research and development programs contribute to the demand for specialized oligonucleotide synthesis, formulation, and manufacturing expertise. Unlike a conventional third-party CDMO, a therapeutics developer primarily advances its own pipeline and may work with external manufacturing partners. Sylentis is therefore relevant to the oligonucleotide ecosystem as a developer of RNA-based medicines, while its role as an external manufacturing service provider should not be assumed without specific supporting evidence.

27. Creative Biogene

Creative Biogene supplies biotechnology research products and services, including nucleic acid-related materials and custom research solutions. Its offerings can support molecular biology, gene research, and early-stage investigations that rely on sequence-specific DNA or RNA products. Such materials may be used during discovery and experimental development of oligonucleotide-based technologies. However, research product supply differs from the regulated production of therapeutic oligonucleotide APIs. Customers should verify the availability of GMP-grade synthesis, purification, analytical testing, and scale-up services before considering Creative Biogene for clinical or commercial manufacturing requirements.

28. Nitto Avecia

Nitto Avecia specializes in oligonucleotide development and manufacturing services for pharmaceutical and biotechnology customers. Its capabilities support therapeutic programs requiring process development, analytical testing, purification, and GMP production. The company serves the growing need for reliable manufacturing of complex nucleic acid-based medicines as candidates progress through clinical development and toward commercialization. Specialized synthesis platforms and quality systems are important for controlling impurities, maintaining product consistency, and supporting regulatory submissions. Nitto Avecia's focus on therapeutic oligonucleotide manufacturing makes it a relevant partner for developers seeking dedicated CDMO expertise.

29. NJ Bio, Inc.

NJ Bio, Inc. provides custom oligonucleotide synthesis and related manufacturing services for research and biotechnology customers. Its capabilities support the preparation of nucleic acid materials for molecular biology, assay development, and applications involving modified or specialized oligonucleotides. Custom synthesis can help researchers obtain sequences tailored to experimental and development needs. Therapeutic manufacturing, however, requires additional controls covering process validation, analytical characterization, impurities, and GMP compliance. Customers should confirm NJ Bio's current manufacturing scale, available modifications, and regulatory quality capabilities before selecting it for clinical-stage or commercial oligonucleotide production.